Spermine-Functionalized Multiepitope Signaling Peptide Nanovaccine to Stimulate the Systemic Immunity against...

Area of Science:

• Nanotechnology
• Immunology
• Vaccine Development

Background:

• Pneumonia poses a significant global health threat with high morbidity and mortality.
• Current vaccines offer limited efficacy due to poor immune response and serotype specificity.
• There is a critical need for advanced vaccine strategies to combat pneumonia.

Purpose of the Study:

• To design and develop a multiepitope signaling peptide nanovaccine (SPM) for enhanced pneumonia protection.
• To utilize dextran (Dex) surface modification and spermine functionalization for improved vaccine delivery and immune activation.
• To evaluate the nanovaccine's physicochemical properties, stability, pH-responsive release, and in vitro/in vivo immunogenicity.

Main Methods:

• Synthesis of spermine-modified acetalated dextran nanoparticles (AcDx-Sp NPs) loaded with signaling peptide motif (SPM).
• Characterization of nanoparticle size, morphology, stability, and pH-dependent drug release kinetics.
• In vitro assessment of dendritic cell activation and pro-inflammatory cytokine production.
• In vivo immunization of mice to evaluate antibody titers, T-cell responses (CD4+, CD8+), and IgA/IgG production.
• Bacterial neutralization assays and advanced imaging (confocal, HRTEM) to confirm efficacy.

Main Results:

• AcDx-Sp NPs exhibited uniform spherical morphology (105 nm) with high SPM loading and stability.
• The nanovaccine demonstrated pH-responsive SPM release, facilitating endosomal escape at acidic pH.
• In vitro studies showed significant dendritic cell activation and a 200-fold increase in pro-inflammatory cytokines.
• In vivo immunization resulted in elevated antibody titers, robust CD4+ and CD8+ T-cell responses, and strong IgA/IgG production.
• The nanovaccine effectively neutralized bacteria, confirming its therapeutic potential.

Conclusions:

• The developed nanovaccine effectively targets antigen-presenting cells and possesses inherent adjuvant properties.
• The engineered nanovaccine elicits potent systemic immunity and demonstrates significant bacterial neutralization capabilities.
• This novel nanovaccine platform holds promise as an effective strategy against bacterial pneumonia pathogenesis.